Vidhya Murthy

Birmingham, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 24 publications

Venetoclax-based non-intensive combinations for relapsed/refractory acute myeloid leukaemia-Real-world data from a UK-wide programme.

Venetoclax-based non-intensive combinations for relapsed/refractory acute myeloid leukaemia-Real-world data from a UK-wide programme.

Journal: British journal of haematology

Published: January 21, 2025

Venetoclax-Azacitidine Salvage Chemotherapy in Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome: A Single-Center Experience.

Venetoclax-Azacitidine Salvage Chemotherapy in Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome: A Single-Center Experience.

Journal: Journal of hematology

Published: October 09, 2024

Real-world outcomes of newly diagnosed AML treated with venetoclax and azacitidine or low-dose cytarabine in the UK NHS.

Real-world outcomes of newly diagnosed AML treated with venetoclax and azacitidine or low-dose cytarabine in the UK NHS.

Journal: Blood neoplasia

Published: April 15, 2024

Extramedullary chronic phase chronic myeloid leukaemia (CML) involving the central nervous system: A case report.

Extramedullary chronic phase chronic myeloid leukaemia (CML) involving the central nervous system: A case report.

Journal: EJHaem

Published: April 03, 2024

Immune-monitoring of myelodysplastic neoplasms: Recommendations from the i4MDS consortium.

Immune-monitoring of myelodysplastic neoplasms: Recommendations from the i4MDS consortium.

Journal: HemaSphere

Published: January 31, 2024

AML in the elderly-A global view.

AML in the elderly-A global view.

Journal: British journal of haematology

Published: September 20, 2023

Venetoclax-based low intensity therapy in molecular failure of NPM1-mutated AML.

Venetoclax-based low intensity therapy in molecular failure of NPM1-mutated AML.

Journal: Blood advances

Published: June 30, 2023

Molecular MRD is strongly prognostic in patients with NPM1-mutated AML receiving venetoclax-based nonintensive therapy.

Molecular MRD is strongly prognostic in patients with NPM1-mutated AML receiving venetoclax-based nonintensive therapy.

Journal: Blood

Published: June 20, 2023

Long-term follow-up of VIALE-C in patients with untreated AML ineligible for intensive chemotherapy.

Long-term follow-up of VIALE-C in patients with untreated AML ineligible for intensive chemotherapy.

Journal: Blood

Published: May 23, 2022

Author Correction: 6-month follow-up of VIALE-C demonstrates improved and durable efficacy in patients with untreated AML ineligible for intensive chemotherapy.

Author Correction: 6-month follow-up of VIALE-C demonstrates improved and durable efficacy in patients with untreated AML ineligible for intensive chemotherapy.

Journal: Blood cancer journal

Published: October 27, 2021

6-month follow-up of VIALE-C demonstrates improved and durable efficacy in patients with untreated AML ineligible for intensive chemotherapy (141/150).

6-month follow-up of VIALE-C demonstrates improved and durable efficacy in patients with untreated AML ineligible for intensive chemotherapy (141/150).

Journal: Blood cancer journal

Published: April 13, 2021

Spindle cell morphology in myeloma.

Spindle cell morphology in myeloma.

Journal: British journal of haematology

Published: March 03, 2021

Showing 1-12 of 24

Last Updated: 09/26/2026